Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 2/20 | 0.55 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.39 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | BID | P55957 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026142 | 0.94 | FEN1 (0.57) | FEN1ERCC1ERCC4RNASEH1 | |
| SCHEMBL4029845 | 0.86 | FEN1 (0.51) | FEN1ERCC1ERCC4RNASEH1 | |
| SCHEMBL4034580 | 0.85 | LTB4R (0.39) | FEN1ERCC1ERCC4LTB4RPLA2G4A | |
| Trifluoroacetic Acid SCHEMBL4027225 | 0.80 | FEN1 (0.47) | FEN1ERCC1ERCC4NLRP3L3MBTL1 | |
| SCHEMBL4028018 | 0.79 | ERCC1 (0.49) | FEN1ERCC1ERCC4L3MBTL1 | |
| SCHEMBL6436946 | 0.76 | FEN1 (0.62) | FEN1ERCC1ERCC4RNASEH1 | |
| SCHEMBL4027678 | 0.76 | FEN1 (0.62) | FEN1ERCC1ERCC4RNASEH1 | |
| Hydrochloric Acid SCHEMBL4031283 | 0.75 | FEN1 (0.60) | FEN1ERCC1ERCC4RNASEH1 | |
| SCHEMBL4025695 | 0.75 | ERCC1 (0.49) | FEN1ERCC1ERCC4L3MBTL1 | |
| SCHEMBL4034573 | 0.74 | ERCC1 (0.57) | FEN1ERCC1ERCC4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | claimed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | claimed |
| EP-1470113-B1 | PYRIMIDINONE VIRAL POLYMERASE INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-01-07 | — | — | EP | disclosed |
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130997-A1 | Pyrimidinone viral polymerase inhibitors | POLR2A, POLR1E, POLR2E | FEN1 343/4885ERCC1 3181/4885ERCC4 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.